CD33 and acute myeloid leukemia: In 2000, GO was approved by the FDA as the first monoclonal antibody conjugate for the treatment of CD33+ AML at a dose of 9 mg/m2, administered as an intravenous infusion, every 14 days for 28-day cycles [127].